Purpose: Idiopathic intracranial hypertension (IIH) is characterized by raised intracranial pressure (ICP), normal cerebrospinal composition and exclusion of alternative causes to increased ICP. The aim of this study was to evaluate longterm visual outcome in a Danish population of IIH patients. Results: Best-corrected visual acuity (BCVA) was reduced in 25% of eyes at V0, in 10% at V1 and in 15% at V2. Colour vision was barely affected. Visual field (VF) was affected (>grade 0) in 87% of eyes at V0 and VF defect grade significantly improved by 0.58 at V1 (p-value <0.0001) and by 0.55 at V2 (p-value <0.001). The most common type of VF defect at V0 was a nerve fibre layer defect (56.4%), and the second most common type was an enlarged blind spot (20.5%). There was no correlation between BCVA and VF defect type. Mean grade of papilloedema decreased from 2.2 at V0 to 0.5 at V2. The grade of papilloedema at V2 was not significantly related to the severity of papilloedema at V0 (p-values 0.65 and 0.48). Conclusion: Idiopathic intracranial hypertension (IIH) is associated with longterm loss of visual function, and relevant treatment strategies need to be improved.
Introduction
Idiopathic intracranial hypertension (IIH) is characterized by raised intracranial pressure (ICP), normal cerebrospinal composition and exclusion of alternative causes to increased ICP (Wall 2017 ). The incidence is highest among young overweight women.
Visual function is often affected in IIH patients, and visual field (VF) is most sensitive to detect deterioration of visual function in the course of IIH (Rowe 2011) . Although a substantial risk of progressive and permanent loss of best-corrected visual acuity (BCVA) is present (Corbett et al. 1982) , BCVA and colour vision usually remain relatively spared until late. Papilloedema can range from mild to severe (Scott et al. 2010) .
Previous outcome studies have reported abnormal baseline visual acuity in about 20% (Corbett et al. 1982; Wall & George 1991) and baseline VF defects in 16 to 82% (Corbett et al. 1982; Rowe & Sarkies 1998) of IIH patients. Outcome visual acuity in a study from 1982 by Corbett et al. was reported as 25% blindness (visual acuity <0.1 or VF<20°) (Corbett et al. 1982) . More recent studies have shown better outcomes with less than 10% of blindness (Wall & George 1991; Rowe & Sarkies 1998) . Papilloedema about grade 2 on the Modified Fris en Score (MFS) has been reported at baseline (Wall & George 1991; Yri et al. 2012) , with total remission as the final outcome (Yri et al. 2012) . No significant correlation was found between papilloedema grade and severity of visual function loss, that is, VF defects, Snellen VA, contrast sensitivity or colour plate testing (Wall & George 1991) .
The Danish Headache Center (DHC) and Department of Ophthalmology, Rigshospitalet -Glostrup are health centres with a special interest in IIH. We wanted to investigate whether the visual outcome of our IIH population correlated to the outcome studies mentioned.
With this in mind, the objective of this study was to evaluate long-term visual outcome in a Danish population of medically treated IIH patients during a follow-up period of 13 months.
Patients and Methods

Study population
From June 2007 to March 2013, 105 patients were diagnosed with IIH at the DHC, Department of Neurology and Department of Ophthalmology, Rigshospitalet -Glostrup. We retrospectively reviewed charts and examinations from all patients who met the modified Dandy criteria for IIH (Wall 2010) .
Inclusion criteria were as follows: unequivocal optic disc oedema, a minimum age of 16 years at time of diagnosis and at least one of two follow-up visits. Exclusion criteria were as follows: potentially other causes of visual loss than IIH; unreliable autoperimetry (false-positive errors and false-negative errors >20% or false-positive errors >20%); missing information about date of onset or recurrence; treatment initiated by other hospitals before attending Rigshospitalet -Glostrup.
Forty-one patients were eligible and included in this study. Thirty-one patients missed both follow-up visits within a year after diagnosis, 11 patients had other potential causes of visual loss than IIH, eight patients had treatment initiated by other hospitals, seven patients did not have unequivocal disc oedema, and seven patients were lacking information about date of onset or recurrence.
We chose the eye with the highest degree of papilloedema at baseline as the study eye. If both eyes had equal degree of papilloedema, we chose the right eye.
Patients gave informed consent. The study followed the tenets of the Declaration of Helsinki, and ethical approval was granted (H-3-2001-016 and H-KA20070003) .
Data collection
Due to a previous protocol, most patients in this study were seen at 1, 3, 6 and 12 months after diagnosis. The effect of medically treated IIH usually appears within 2 months (Wall & George 1991) . We wanted to study patients before and after the full treatment effect. Thus, we retrospectively defined three study points: baseline visit at 0-2 months (V0), follow-up visit 1 at 2-6 months (V1) and follow-up visit 2 at 6-13 months (V2).
At baseline, we recorded age, gender, weight, height and lumbar cerebrospinal fluid (CSF) pressure. All patients had CSF analysis, computed tomography (CT), often computed tomography with venous sequence (CTV) and magnetic resonance imaging (MRI) of the brain, and ophthalmological as well as neurological examination to exclude alternative causes of visual loss or intracranial hypertension.
Best-corrected visual acuity (BCVA) and colour vision
We measured best-corrected Snellen visual acuity (BCVA) and converted it to a logMar scale for statistical analysis before converting back to a linear scale (0-1.6). We defined values from 1 to 1.6 as normal BCVA. We assessed colour vision with Ishihara plates (number of correctly identified plates out of 17 possible).
Papilloedema
Two experienced neuro-ophthalmologists (MW and SH) evaluated blinded fundus photographs according to the MFS with intermediate grades, first used by Scott et al. (2010) . Grade 0 was equal to no papilloedema. Grade 0.5-2 was defined as mild-to-moderate papilloedema, whereas 2.5-5 was defined as moderate-to-severe papilloedema. Furthermore, optic disc atrophy was registered. In case of interreviewer variability on MFS grade, a final grade was chosen following a predefined system, Appendix 1. In case of disagreements by more than one grade, consensus between the neuroophthalmologists was obtained by a collective review.
Visual field (VF)
We assessed VF using automated perimetry (Octopus; Haag-Streit, Koeniz, Switzerland) with the examination strategy DG30. The two neuroophthalmologists independently evaluated the blinded VFs according to an autoperimetry mean deviation grading scale slightly modified from Shah et al. (2008) and defined in Appendix 2. They further classified the type of VF defect: concentric, central, nerve fibre layer (NFL), enlarged blind spot (EBS) or diffuse. In case of classification disagreements, a collective review ensured consensus.
Statistics
The difference in distribution of papilloedema grade at the three visits was tested by applying Fishers Exact Test. To compare the changes in BCVA from V0 to V1 and from V0 to V2, we analysed the data in a linear mixed effects model, which assumed an exchangeable (compound symmetry) correlation structure. Using the same method, we examined the correlation between BCVA during the whole observation period and VF defect grade, VF defect type and papilloedema, respectively. We used Wald test statistic to test the correlation between VF type and BCVA. We used chi-squared test to test the correlation between papilloedema at V0 and VF type at V2. With Pearson's correlation, we estimated the correlation between papilloedema at V0 and VF grade at V2. We performed statistical analyses with R version 3.2.0. (2015-04-16 ) and modelling with the statistical software package R, version 1.2.0 (downloadable at: http://cran.r-project.org/).
Results
Demographics
We analysed data from 41 eyes from 41 patients at V0, 38 eyes from 38 patients at V1 and 35 eyes from 35 patients at V2. All patients were women. Thirtyseven (90.2%) were newly diagnosed with IIH, whereas four (9.8%) had relapsing IIH. The meantime to recurrence was 4 years (AE0.9; range: 3-5.5). Meantime from diagnosis to V0 in our clinics was 2 days [standard deviation (SD) At V0, mean converted BCVA was 1.0 (SD: 0.29; range: 0.1-1.6), Table 1 . Best-corrected visual acuity (BCVA) was normal (equal to or above 1.0) in 30 of 40 eyes (75%). At V0, two eyes had BCVA <0.5. One eye with BCVA of 0.1 had a severe papilloedema (grade 4.5) and no VF defect. Another eye with BCVA of 0.4 had a moderate papilloedema (grade 2) and a mild VF defect (grade 1). At V1, BCVA was normal in 27 of 30 eyes (90%). Mean BCVA was 1.2 (SD: 0.25; range: 0.8-1.6). At V2, BCVA was normal in 28 of 33 eyes (85%). Mean BCVA was 1.1 (SD: 0.25; range: 0.6-1.6). Only two eyes had BCVA of 0.6.
A statistical subanalysis of individual visual acuity showed that BCVA increased 0.19 (CI: 0.09; 0.29) between V0 and V1 (p-value 0.0001), and 0.12 (CI: 0.02; 0.21) between V0 and V2 (p-value 0.0147), respectively. Best-corrected visual acuity (BCVA) significantly increased for each patient during the whole study period (correlation estimate a = 0:379).
Colour vision
At V0, mean colour vision score was 15.7 (SD: 3.91; range: 0-17). Two eyes had a score of 0. The first eye had BCVA of 0.1, whereas the second had 0.63. At V1, we found mean colour vision score of 16.8 (SD: 0.76; range: 13-17). Mean colour vision was also 16.8 at V2 (SD: 0.56; range: 15-17), 
Papilloedema
At V0, 22 eyes had mild-to-moderate papilloedema and 14 eyes had moderate-to-severe papilloedema, Table 1 . Mean papilloedema grade was 2.2 (SD: 1.13; range: 1-4.5) at V0 and decreased to 0.4 (SD: 0.70; range: 0-2.5) at V1. It stabilized at 0.5 (SD: 0.79; range: 0-3.5) at V2, Table 1 . Papilloedema had resolved completely in 16 of 26 eyes (61.5%) at V1 and in yet another eye at V2. One eye remained with severe papilloedema (3.5) at V2, and this was in parallel to a worsening in VF defect grade throughout the study period. Best-corrected visual acuity (BCVA) in this patient was normal.
At V2, there was no difference in papilloedema grade between eyes that had presented with mild-moderate papilloedema and those that presented with moderate-severe papilloedema at V0 (p-values, respectively, 0.65 and 0.48).
From V0 to V2, eyes with grade 0.5-2 papilloedema yielded a larger BCVA improvement by 0.0425 (-0.154; 0.239) compared to eyes with grade 2.5-5; nevertheless, the difference was not significant (p-value 0.67).
Visual field defect grade
Visual field (VF) defect grade ranged from 0 to 3 throughout the study period, Table 1 . Mean VF defect grade was 1.3 (SD: 0.71; range: 0-3) at V0. Mean VF defect grade improved to 0.7 (SD: 0.70; range: 0-2) at V1 and stabilized at 0.8 (SD: 0.83; range: 0-2) at V2.
VF defect grade for each eye significantly improved by 0.58 (CI: À0.80; À0.36) from V0 to V1 (p-value <0.0001). A similar improvement in VF defect grade by 0.55 (CI: À0.86; À0.23) was seen from V0 to V2 (p-value <0.001).
There was no significant correlation between papilloedema at V0 and VF defect grade at V2 (p-value 0.81).
Visual field defect type
At V0, 34 of 39 eyes (87%) had a VF defect. At V1, 20 of 35 eyes (57%) had a VF defect. At V2, 16 of 30 eyes (53%) had a VF defect.
At V0, the most common VF defect types were NFL (56.4%) and EBS (20.5%), Table 2 . Number of eyes with NFL decreased (improved) to, respectively, 28.6% at V1 and 43.3% at V2. Number of eyes with EBS decreased (improved) to, respectively, 20% at V1 and 6.7% at V2. At V0, only few eyes had a concentric (2.6%) and central (2.1%) defect. No eyes remained with a concentric nor central defect at V2.
There was no significant correlation between VF defect type at V0 and BCVA during the whole observation period (p-value >0.05).
There was no significant correlation between papilloedema at V0 and VF defect type at V2 (p-value 0.57).
Discussion
The aim of this retrospective study was to evaluate visual function in 41 patients diagnosed with IIH at Rigshospitalet -Glostrup between June 2007 and March 2013.
We found that VF was affected and that papilloedema in some patients was present throughout the follow-up period. About half of our patients had a VF defect (primarily NFL) at endpoint (VF grade 0-2). Mean papilloedema score improved by more than 1.5 grade from baseline to end-point (from 2.2 to 0.5). Mean BCVA was normal (at least 1.0) throughout the study period. Colour vision was not affected. We found less severe VF defect grade comparing to Rowe and Sarkies (Rowe & Sarkies 1998) [97% minimal or mild VF defect at baseline (V0) versus 67%]. With a mean VF defect grade of 1.3 at baseline (V0), our results may be similar to the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) baseline clinical profile (Wall et al. 2014) where the average grade of the worse study eye was 1. As in other studies, we found there was no significant correlation between BCVA and VF defect (Wall & George 1991; Rowe & Sarkies 1998) . We noted that VF defect types at baseline (V0) were mostly localized as nerve fibre bundle type, which was also found in the IIHTT (Keltner et al. 2014 ). We used a VF defect grading scale rather than the perimetric mean defect value directly, which is why we cannot directly compare our results to the IIHTT. However, we can confirm that the percentage of EBS decreases with time, as we registered 20% of these defects at baseline and 7% at V2.
Our patients had relatively mild papilloedema with 61% grading ≤2 on the MFS. This is in line with several other studies (Shah et al. 2008; Scott et al. 2010; Yri et al. 2012) . In comparison, baseline papilloedema was mostly moderate to severe (grade 2-4) in the IIHTT Optical coherence tomography Baseline Study (OCT Sub-Study Committee for NORDIC Idiopathic Intracranial Hypertension Study Group et al. 2014) . At our final follow-up at 13 months, around 40% of eyes remained with papilloedema. This is less compared to a prospective study by Wall and George (1991) , where 64% of eyes had papilloedema at final visit (follow-up 2-39 months). As papilloedema damages optic nerve fibres, we hypothesized that increasing amount of papilloedema at diagnosis would cause increased VF loss. However, we did not find a correlation between papilloedema at baseline (V0) and VF defect at end-point (V2). In line with this, no significant correlation between papilloedema grade and loss of VF grade was found in the study mentioned above (Wall & George 1991) . We found no correlation between severity of papilloedema at diagnosis and BCVA throughout the study period, which also agrees with the study by Wall and George (1991) . However, due to the small sample, we could not exclude that moderate-tosevere papilloedema at baseline was correlated to lower end-point BCVA up to 0.15 units on converted Snellen BCVA scale compared to end-point BCVA in patients with mild-to-moderate papilloedema at baseline. To determine if there is such a correlation, a study with more patients is needed. Thus, it seems that clinicians should not be more worried about the BCVA in a patient with severe papilloedema versus one with mild papilloedema.
Baseline (V0) BCVA was similar to the IIHTT with 75% of eyes showing BCVA 20/20 or above (Wall et al. 2014) . Interestingly, the BCVA in patients in this retrospective cohort increased over time. This might imply that adequate treatment and follow-up of IIH have a beneficial effect. These results support data published in three previous follow-up studies (Shah et al. 2008; Skau et al. 2011; Yri et al. 2012) . Patients in our study had a relatively good result concerning BCVA, as no patient's eye became blind within 13 months. Furthermore, colour vision was unaffected and remained stable throughout follow-up. This is a better outcome compared to a finding of 20% colour plate loss at baseline in the study by Wall and George (1991) .
Strength of this study includes short time interval between onset of symptoms and first visit at our departments (mean 2 days), systematic follow-up intervals as well as standardized examination, due to a previous protocol (Skau et al. 2011 ). Our patients were followed up for several months and were examined by the same two neuroophthalmologists. Moreover, patient demographics were similar to prior studies except for slightly less obesity in the present study (Kesler et al. 2004; Wall et al. 2014 ). This should allow direct comparison of results and may challenge the causality of obesity in the pathogenesis of IIH.
The study was limited by its retrospective nature as well as missing data when patients failed to show up to appointments. Reasons for this can be long transportation for people living outside of Copenhagen and compliance problems due to, that is, severe headache and cognitive complaints (Yri et al. 2012) . Data may thus be flawed by a 'selection bias' in terms of patients with the better outcome being the ones to show up at follow-up visits. Other challenges were low reliability factors during autoperimetry, thus failing the inclusion criteria of the study.
In conclusion, visual outcome in the present Danish population of IIH patients seems better compared to previous studies. Best-corrected visual acuity (BCVA) is generally good at baseline and further improves from 0 to 6 months. From this as well as previous studies, we can conclude that clinicians should attach less importance to BCVA, as it is rarely severely affected. In contrast to this, it is important to monitor VFs, as they improve significantly during the first 6 months. Lastly, papilloedema is less severe comparing to previous studies and our patients experienced rapid improvement of papilloedema grade within the first 6 months. There was no significant correlation between severity of papilloedema at time of diagnosis and final visual outcome. In contrast to other studies, no patients became blind in terms of visual acuity or VF at follow-up. However, about half of our patients had affected VF after 1 year. A dedicated team effort as well as awareness of IIH is therefore still important due to the association of IIH with loss of visual function. V0: 0-2 months, V1: 2-6 months, V2: 6-13 months. CEN = central, CON = concentric, DIF = diffuse, EBS = enlarged blind spot, NFL = nerve fibre layer, VF = visual field.
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